Cargando…
Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
The early remission of diabetic macular edema (DME) often occurs in eyes treated with anti-vascular endothelial growth factor (VEGF) treatment. We retrospectively reviewed and characterized eyes with early remission of DME at six months in 80 eyes under pro re nata (PRN) intravitreal ranibizumab (IV...
Autores principales: | Yoshitake, Tatsuya, Murakami, Tomoaki, Suzuma, Kiyoshi, Fujimoto, Masahiro, Dodo, Yoko, Tsujikawa, Akitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527559/ https://www.ncbi.nlm.nih.gov/pubmed/31110273 http://dx.doi.org/10.1038/s41598-019-44078-6 |
Ejemplares similares
-
Hyperreflective Foci in the Outer Retinal Layers as a Predictor of the Functional Efficacy of Ranibizumab for Diabetic Macular Edema
por: Yoshitake, Tatsuya, et al.
Publicado: (2020) -
Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema
por: Mori, Yuki, et al.
Publicado: (2017) -
Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema
por: Mori, Yuki, et al.
Publicado: (2016) -
Anti-Hexokinase 1 Antibody as a Novel Serum Biomarker of a Subgroup of Diabetic Macular Edema
por: Yoshitake, Tatsuya, et al.
Publicado: (2019) -
Decorrelation Signal of Diabetic Hyperreflective Foci on Optical Coherence Tomography Angiography
por: Murakami, Tomoaki, et al.
Publicado: (2018)